Ponezumab: Difference between revisions

Revision as of 01:28, 6 April 2023 editEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,391 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper ← Previous edit		Revision as of 05:36, 26 November 2023 edit undoBuidhe (talk \| contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,149 edits removed Category:Treatment of Alzheimer's disease; added Category:Anti-amyloid monoclonal antibodies using HotCat Next edit →
Line 53:		Line 53:

	]		]
	]		]
	]		]

Revision as of 05:36, 26 November 2023

Monoclonal antibody Pharmaceutical compound

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.

"Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
"Alzforum".

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Human	Stamulumab

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.